All In Biotech

Drug Trial Radar · NCT05219968

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults

Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Jan 27, 2022

Primary completion

Mar 4, 2024

Study completion Sep 16, 2024

Sponsor

Lead sponsor
Lyra TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.

Conditions

  • Chronic Sinusitis
  • Chronic Rhinosinusitis (Diagnosis)

Interventions

  • LYR-210Drug

    LYR-210 drug matrix (mometasone furoate)

  • Sham procedure controlDrug

    Sham procedure control

  • Background TherapyOther

    Daily Saline Irrigation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps.Time frame: 24 Weeks

Locations

55 sites in 5 countries. Site status is shown where the registry gives one.

  • Lyra Investigational Site

    Birmingham, Alabama

  • Lyra Investigational Site

    Escondido, California

  • Lyra Investigational Site

    La Mesa, California

  • Lyra Investigational Site

    Sacramento, California

  • Lyra Investigational Site

    Torrance, California

  • Lyra Investigational Site

    Boca Raton, Florida

  • Lyra Investigational Site

    Boynton Beach, Florida

  • Lyra Investigational Site

    Plantation, Florida

  • Lyra Investigational Site

    Port Saint Lucie, Florida

  • Lyra Investigational Site

    Chicago, Illinois

  • Lyra Investigational Site

    Louisville, Kentucky

  • Lyra Investigational Site

    Baltimore, Maryland

  • Lyra Investigational Site

    New Hyde Park, New York

  • Lyra Investigational Site

    New York, New York

  • Lyra Investigational Site

    New York, New York

  • Lyra Investigational Site

    New York, New York

  • Lyra Investigational Site

    Winston-Salem, North Carolina

  • Lyra Investigational Site

    Charleston, South Carolina

  • Lyra Investigational Site

    Spartanburg, South Carolina

  • Lyra Investigational Site

    Nashville, Tennessee

  • Lyra Investigational Site

    Fort Worth, Texas

  • Lyra Investigational Site

    Houston, Texas

  • Lyra Investigational Site

    Mansfield, Texas

  • Lyra Investigational Site

    San Antonio, Texas

  • Lyra Investigational Site

    South Ogden, Utah

  • Lyra Investigational Site

    Norfolk, Virginia

  • Lyra Investigational Site

    Graz, Austria

  • Lyra Investigational Site

    Klagenfurt, Austria

  • Lyra Investigational Site

    Linz, Austria

  • Lyra Investigational Site

    Vienna, Austria

  • Lyra Investigational Site

    Brno, Czechia

  • Lyra Investigational Site

    Hradec Králové, Czechia

  • Lyra Investigational Site

    Motol, Czechia

  • Lyra Investigational Site

    Olomouc, Czechia

  • Lyra Investigational Site

    Prague, Czechia

  • Lyra Investigational Site

    Bydgoszcz, Poland

  • Lyra Investigational Site

    Bydgoszcz, Poland

  • Lyra Investigational Site

    Elblag, Poland

  • Lyra Investigational Site

    Katowice, Poland

  • Lyra Investigational Site

    Krakow, Poland

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.